Results 41 to 50 of about 77,609 (253)

A new paradigm evaluating cost per cure of HCV infection in the UK [PDF]

open access: yes, 2016
Background: New interferon (IFN)-free treatments for hepatitis C are more effective, safer but more expensive than current IFN-based therapies. Comparative data of these, versus current first generation protease inhibitors (PI) with regard to costs and ...
Aline Gauthier   +7 more
core   +2 more sources

Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing.

open access: yesPLoS Neglected Tropical Diseases, 2022
Ribavirin is currently the standard of care for treating Lassa fever. However, the human clinical trial data supporting its use suffer from several serious flaws that render the results and conclusions unreliable.
Alex P Salam   +7 more
doaj   +1 more source

A Case of Obstructive Jaundice due to Bile Duct Tumor Thrombus of Hepatocellular Carcinoma Diagnosed by Peroral Cholangioscopy

open access: yesDEN Open, Volume 6, Issue 1, April 2026.
Abstract While hepatocellular carcinoma (HCC) often invades the portal or hepatic vein to form tumor thrombus, tumor thrombus in the bile duct is rare. In such cases, differentiation from intrahepatic cholangiocarcinoma is difficult, and the tumor often appears as a smooth, yellowish‐white, polypoid mass within the bile duct lumen.
Keisuke Kinoshita   +9 more
wiley   +1 more source

Era of direct acting anti-viral agents for the treatment of hepatitis C. [PDF]

open access: yes, 2018
Hepatitis C infection is universal and the most common indication of liver transplantation in the United States. The period of less effective interferon therapy with intolerable side effects has gone.
Ahmed, Monjur
core   +1 more source

Cryoglobulinaemic vasculitis: classification and clinical and therapeutic aspects [PDF]

open access: yes, 2007
Cryoglobulinaemia may cause cutaneous vasculitis and glomerulonephritis, potentially leading to end stage renal failure. An important proportion of cryoglobulinaemias are secondary to hepatitis C virus infection.
Braun, Gerald S.   +4 more
core   +2 more sources

Ribavirin and its analogs: Сan you teach an old dog new tricks?

open access: yesТонкие химические технологии, 2019
The review article focuses on the current state of synthetic and biological studies of ribavirin analogs. Ribavirin is a broad-spectrum nucleoside antiviral drug with a 50-year long history of research and application, but its mechanism of action still ...
M. V. Chudinov
doaj   +1 more source

Crystallization Selectivity of Ribavirin Solution and Amorphous Phase

open access: yesMolecules, 2023
Crystallization selectivity is an important principle in polymorph control. Ribavirin Form I, Form II, DMSO solvate, and amorphous ribavirin are prepared, and the short-range order similarities between these solid forms and ribavirin aqueous solution and
Fuying Li   +6 more
doaj   +1 more source

20 Years of Liver Biopsies at a Single Institution—Application of a Machine Learning‐Based Approach to Pathology Database Searches

open access: yesLiver International Communications, Volume 7, Issue 1, March 2026.
ABSTRACT Advances in hepatology—such as noninvasive serum biomarkers (e.g., Fibrosure since 2004), imaging techniques (e.g., MR Elastography since 2009 and FibroScan since 2013), and effective direct‐acting antivirals for the treatment of chronic hepatitis C—have likely influenced liver biopsy practices.
Nazire E. Albayrak   +8 more
wiley   +1 more source

Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis. [PDF]

open access: yes, 2017
Long-term functional outcomes of sofosbuvir-based antiviral treatment were evaluated in a cohort study involving 16 Italian centres within the international compassionate use programme for post-transplant hepatitis C virus (HCV) recurrence. Seventy-three
Burra, Patrizia   +2 more
core   +1 more source

Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial

open access: yesAnnals of Hepatology, 2003
Treatment with polyethylene glycol-modified interferon alfa-2a (peginterferon) alone produces significantly higher sustained antiviral responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection.
Francisco Bosques-Padilla, MD   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy